Screener
BridgeBio Pharma BBIO Total Revenue
Total Revenue at other companies
Segments
Other financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: BridgeBio Pharma’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:31 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001743881-26-000019
| Line item | Three Months Ended March 31, 2026 | 2025 |
|---|---|---|
| Net product revenue | $180,596 | $36,739 |
| License and services revenue | 4,419 | 79,690 |
| Royalty revenue | 9,500 | 204 |
| Total revenues, net | 194,515 | 116,633 |
| Operating costs and expenses: | ||
| Cost of revenues: | ||
| Cost of goods sold | 7,732 | 2,034 |
| Cost of license, services, and royalty revenue | 2,207 | 605 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is BridgeBio Pharma's total revenue?
- BridgeBio Pharma (BBIO) reported total revenue of $194.52M in Q1 2026.
- How has BridgeBio Pharma's total revenue changed year-over-year?
- BridgeBio Pharma's total revenue increased by 66.8% year-over-year, from $116.63M to $194.52M.
- What is the long-term trend for BridgeBio Pharma's total revenue?
- Over 4 years (2021 to 2025), BridgeBio Pharma's total revenue has grown at a 63.8% compound annual growth rate (CAGR), from $69.72M to $502.08M.
- What does total revenue mean?
- The aggregate of all revenue from the company's operations — the top line from which all profitability metrics are derived.
Ask your AI about BridgeBio Pharma's total revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude